These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 4839098)

  • 21. [Therapy of Parkinsonian syndrome using L-dopa. Current state and problems].
    Fischer PA
    Nervenarzt; 1974 Dec; 45(12):617-27. PubMed ID: 4614096
    [No Abstract]   [Full Text] [Related]  

  • 22. Levodopa and pressor amine sensitivity in parkinsonism.
    Reid JL; Calne DB; George CF; Vakil SD
    Clin Pharmacol Ther; 1972; 13(3):400-6. PubMed ID: 5026378
    [No Abstract]   [Full Text] [Related]  

  • 23. Failures of L-dopa.
    Paulson GW
    Ohio State Med J; 1973 Dec; 69(12):896-8. PubMed ID: 4769406
    [No Abstract]   [Full Text] [Related]  

  • 24. [Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination].
    Boudin G; Pepin B; Guillard A; Godlewski S; Fabiani JM; Haguenau M
    Rev Neurol (Paris); 1974; 130(7-8):273-84. PubMed ID: 4217929
    [No Abstract]   [Full Text] [Related]  

  • 25. Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy.
    Korf J; van Praag HM; Schut D; Nienhuis RJ; Lakke JP
    Eur Neurol; 1974; 12(5-6):340-50. PubMed ID: 4448192
    [No Abstract]   [Full Text] [Related]  

  • 26. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A
    Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of pyridoxal phosphate and L-dopapyridoxal phosphate on DOPA decarboxylase activity.
    Tran N
    Experientia; 1972 Sep; 28(9):1021-2. PubMed ID: 4665286
    [No Abstract]   [Full Text] [Related]  

  • 28. Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.
    Brogden RN; Speight TM; Avery GS
    Drugs; 1971; 2(4):262-400. PubMed ID: 4340597
    [No Abstract]   [Full Text] [Related]  

  • 29. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
    Klawans HL; Ringel SP; Shenker DM
    J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):682-6. PubMed ID: 5158783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Parkinsonism with L-dopa and decarboxylase inhibitors. An electrophysiological study.
    Dietrichson P
    Acta Neurol Scand Suppl; 1972; 51():111-3. PubMed ID: 4514333
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effect of a decarboxylase inhibitor (Ro 4-4602) in combination with L-dopa on inhibited depressions].
    Matussek N; Benkert O; Schneider K; Otten H; Pohlmeier H
    Arzneimittelforschung; 1970 Jul; 20(7):934-5. PubMed ID: 4918921
    [No Abstract]   [Full Text] [Related]  

  • 32. [Two years experience with L-DOPA in association with a decarboxylase inhibitor].
    Siegfried J
    Rev Neurol (Paris); 1970 Apr; 122(4):243-8. PubMed ID: 5472041
    [No Abstract]   [Full Text] [Related]  

  • 33. Aterial blood pressure in dogs: effects of m-tyrosine alone or in combination with inhibitors of aromatic amino acid decarboxylase; relative hypotensive potencies of L-dopa, DL-m-tyrosine, and L-m-tyrosine.
    Minsker DH; Stokes AL
    Experientia; 1974 Sep; 30(9):1051-3. PubMed ID: 4412113
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of L-dopa administration on growth hormone secretion in normal subjects and Parkinsonian patients.
    Cavagnini F; Peracchi M; Scotti G; Raggi U; Pontiroli AE; Bana R
    J Endocrinol; 1972 Sep; 54(3):425-33. PubMed ID: 5071365
    [No Abstract]   [Full Text] [Related]  

  • 36. The cardiovascular pharmacology of L(--)-dopa: peripheral and central effects.
    Osborne MW; Wenger JJ; Willems W
    J Pharmacol Exp Ther; 1971 Sep; 178(3):517-28. PubMed ID: 5571901
    [No Abstract]   [Full Text] [Related]  

  • 37. [Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
    Geissbühler F; Gaillard JM; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Eur Etud Clin Biol; 1972 Jan; 17(1):38-44. PubMed ID: 5041348
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of parkinsonism with the drug L-DOPA].
    Stoliarova LG; Kistenev BA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):199-205. PubMed ID: 4795170
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of Parkinson's disease with L-dopa: a current appraisal.
    Kofman O
    Can Med Assoc J; 1971 Mar; 104(6):483-7. PubMed ID: 5549988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602].
    Barbeau A; Gillo-Joffroy L; Mars H; Arsenault A
    Rev Can Biol; 1972; 31():Suppl:169-74. PubMed ID: 5052323
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.